Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a…

By D. A. Morrow, C. Cannon, N. Rifai, M. Frey, R. Vicari, N. Lakkis, D. Robertson, D. Hille, P. Delucca, Peter M DiBattiste and 3 more. Journal of the American Medical Association (JAMA), 2001

698 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging, Surgery

View Paper: https://www.semanticscholar.org/paper/c33ff6de51bcc29accefb35c38282c846d794ecc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Joseph S. Alpert
2. D. A. Morrow
3. Robert M. Califf
4. Hani Jneid
5. Judith Hochman
6. Allan S. Jaffe
7. M. Drazner

In Surgery

1. Joseph S. Alpert
2. Robert M. Califf
3. Judith Hochman

Citations in the corpus

• ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients (2002, background): “Thus, both the FRISC II (28,29) and TACTICS-TIMI 18 (7,30) trials, the 2 most recent trials comparing invasive vs.”
• Association of Troponin T Detected With a Highly Sensitive Assay and Cardiac Structure and Mortality Risk in the General Population (2010, positive): “In contrast, in patients with acute coronary syndromes, low levels of troponin correlate with angiographic evidence of greater lesion severity and complexity(32) and identify patients at greater risk for ischemic complications than for death or heart failure.(33,34) Taken together, these findings su”
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “Patients with elevated cardiac troponin benefit from more aggressive therapy, whereas those without elevated cardiac troponins may not.(140) This is especially true for women in whom some data suggest adverse effects from invasive therapies in the absence of an elevated cardiac troponin value.”